Neurocrine’s Phase III trial of valbenazine for DCP fails to meet endpoints
Neurocrine Biosciences has reported that its Phase III trial assessing the selective vesicular monoamine transporter 2 (VMAT2) inhibitor, valbenazine, for…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial
Psyence BioMed has received formal approval from the Bellberry Human Research Ethics Committee (HREC), Australia, to use psychedelic active pharmaceutical…
-
Hutchmed begins Phase I HMPL-A251 clinical development programme
Hutchmed has commenced its worldwide Phase I clinical development programme for a first-in-class phosphoinositide 3-kinase (PI3K) / phosphoinositide 3-kinase-related protein…
-
Northwell Health and START open early-phase cancer trial facility
Northwell Health and the START Center for Cancer Research have inaugurated a $5.7mearly-phase cancer clinical trial centre in the US.…
-
Affibody’s ABY-271 breast cancer trial cleared to progress to next phase
Affibody has received a recommendation from its Trial Review Committee (TRC) to proceed to the second part of its Phase…
-
First patient treated in trial of Beacon Therapeutics’ XLRP treatment
Beacon Therapeutics has treated the first patient in its open-label LANDSCAPE trial of the potential gene therapy, laru-zova (laruparetigene zovaparvovec),…
-
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron replacement cell…
-
argenx to discontinue Phase III trials of thyroid eye disease therapy
argenx has announced the discontinuation of the Phase III UplighTED trials of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in…
-
Alphyn secures $25m in Series B for trial of Zabalafin Hydrogel
Alphyn Biologics has completed $25m in a Series B funding round to support the global Phase IIb trial of its…
-
Anova introduces AI patient matching solution for clinical trials
Anova Enterprises has launched the AnovaOS software-as-a-service (SaaS) platform, a new AI-based patient matching solution for clinical trials. The solution…